Last week was a long, hard week. I pushed through pain, frustrations, difficulties, weariness, weakness, emotional stress, financial strain, the unexpected, and loneliness. If I was to list everything I dealt with the list would actually take pages and pages of...
The Loaded Question: ‘How Are You?’
Last week was a long, hard week. I pushed through pain, frustrations, difficulties, weariness, weakness, emotional stress, financial strain, the unexpected, and loneliness. If I was to list everything I dealt with the list would actually take pages and pages of...
Managing Chronic Pain with MS A Practical Guide for Canadians
For Canadians newly diagnosed with multiple sclerosis and chronic pain, along with the family members trying to support them, the early weeks can feel like living with a moving target. Pain may show up alongside fatigue, spasticity, or nerve symptoms, and the...
Common MS Drug Causes Rare but Potentially Deadly Allergic Reactions, FDA Warns
The U.S. Food and Drug Administration (FDA) has added a so-called “black box” (“boxed warning”) alert to the multiple sclerosis drug Copaxone (glatiramer acetate) and its generic version, Glatopa, because of rare but potentially fatal allergic...
Mavenclad Effect on Quality of Life
Treatment with Mavenclad (cladribine) over two years significantly improved physical and mental health aspects of quality of life in people with highly active relapsing multiple sclerosis, according to a final analysis of data from a Phase 4 study. Mavenclad is an...
Vidofludimus Calcium Reduced RRMS Brain Lesions in EMPhASIS Trial
by Marisa Wexler, MS | June 17, 2022 Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosis (RRMS), data from the Phase 2 EMPhASIS clinical...








